Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflas
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
ICMR will continue to track trends in HMPV circulation throughout the year
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
The collaboration offers opportunities for training, research fellowships, workshops and conferences at palliative care centers managed by Ajit Isaac Foundation
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
Subscribe To Our Newsletter & Stay Updated